About Engage Bio

Engage Bio is a biotechnology company focused on eliminating human diseases through its advanced DNA medicine platform, Tethosomes. It provides this non-immunogenic, highly potent, and redosable gene therapy technology to pharmaceutical companies, biotech firms, and research institutions. The platform is designed to overcome key hurdles in DNA delivery, enabling the development of new genetic medicines.

Company Classification

Customers

Customer	Success Story	Source
UCB	Acquired Engage Therapeutics for US$ 125 million in cash and up to US$ 145 million in potential milestone payments. This acquisition adds Staccato[®] Alprazolam to UCB's portfolio, a drug-device combination for acute on-demand seizure management in epilepsy.
UCB	UCB acquired Engage Therapeutics, including its investigational drug Staccato Alprazolam for active epileptic seizures. UCB also signed an updated license and commercial supply agreement with Alexza Pharmaceuticals for the drug.
Nice Try Sign up to Ethos to access the full customer list Sign up to Ethos	Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.	Source
Another Company	Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.	Source
One More Company	Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Sunt in culpa qui officia deserunt mollit anim id est laborum.	Source
Nice Try	Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.	Source